How Tumour Hypoxia Drives VEGFA Angiogenic Signalling

How Hypoxia Stabilises HIF-1α to Drive the Angiogenic Signalling Programme

Rapidly dividing tumour cells outpace their oxygen supply, creating hypoxic regions with pO2 below 2–5 mmHg. Under normoxic conditions, prolyl hydroxylase domain (PHD) enzymes hydroxylate HIF-1α at Pro402 and Pro564 — an oxygen-requiring reaction. Hydroxylated HIF-1α is recognised by the VHL E3 ubiquitin ligase complex, which ubiquitinates and rapidly degrades HIF-1α (half-life <5 minutes). Hypoxia inhibits PHD enzymes by depleting their oxygen co-substrate, preventing HIF-1α hydroxylation, blocking VHL-mediated degradation, and allowing HIF-1α to accumulate and translocate to the nucleus.

Nuclear HIF-1α dimerises with the constitutively expressed HIF-1β subunit and binds hypoxia response elements (HREs: RCGTG) in the VEGFA promoter, driving 50-fold VEGFA mRNA induction within minutes of hypoxia onset. HIF-1α also transcriptionally activates GLUT1 (glucose transport), LDHA (glycolysis), EPO (erythropoiesis), and PDGFB (pericyte recruitment) — a coordinated hypoxic adaptation programme. Critically, this hypoxia→HIF-1α→VEGFA cascade is also activated by oncogenic signals independent of oxygen status: RAS→ERK signalling, PI3K/AKT→mTOR signalling, and STAT3 activation each drive HIF-1α protein synthesis or stability in normoxic cancer cells, making VEGFA expression a constitutive oncogenic output.

The VEGFR2 Signalling Cascade: From Ligand Binding to Vessel Sprouting

VEGFA165 (the dominant pro-angiogenic isoform) binds VEGFR2 (KDR) on endothelial cells with ~100 pM affinity, inducing receptor homodimerisation and autophosphorylation at multiple tyrosine residues. VEGFR2 Tyr1175 phosphorylation is the primary angiogenic signalling event, recruiting PLCγ and Shb adapter proteins to activate Ca2+/PKC (endothelial proliferation) and PI3K/AKT/mTOR (endothelial survival) downstream signalling cascades. VEGFR2-mediated SRC kinase activation phosphorylates VE-cadherin at Tyr685, loosening endothelial adherens junctions and increasing vascular permeability — the characteristic tumour vessel leakiness that drives oedema and impairs drug delivery.

Vessel sprouting is directed by DLL4/Notch lateral inhibition: high VEGFA gradients at the sprouting front activate DLL4 in leading 'tip cells', which suppresses VEGFR2 expression in adjacent 'stalk cells' through Notch signalling, creating a tip/stalk cell hierarchy that ensures directional vessel growth. ANG2 (angiopoietin-2) secreted by tip cells destabilises pericyte attachment, permitting endothelial migration into the tumour stroma. This coordinated VEGFA→VEGFR2→PI3K/AKT and VEGFA→VEGFR2→SRC/VE-cadherin signalling cascade is the molecular engine of tumour neovascularisation.

Anti-VEGF Agents: Bevacizumab, Ramucirumab, and VEGFR TKIs

Bevacizumab (Avastin) is a humanised anti-VEGFA monoclonal antibody that binds all biologically active VEGFA isoforms, preventing receptor engagement. The pivotal AVF2107 trial (Hurwitz et al., NEJM 2004) demonstrated that adding bevacizumab to irinotecan-based chemotherapy in metastatic colorectal cancer extended median OS from 15.6 to 20.3 months, securing the first anti-angiogenic approval. Bevacizumab is now approved in combination with chemotherapy or targeted agents across colorectal, NSCLC, glioblastoma, renal cell carcinoma, cervical, and hepatocellular cancers. Ramucirumab (anti-VEGFR2 antibody) blocks ligand binding at the receptor level and is approved for gastric, NSCLC, hepatocellular, and colorectal cancers.

VEGFR tyrosine kinase inhibitors (TKIs) — sunitinib, sorafenib, axitinib, cabozantinib, lenvatinib, pazopanib — are multi-targeted agents inhibiting VEGFR1/2/3 alongside PDGFR, KIT, RET, and MET. Their broad kinase inhibition produces greater anti-tumour activity through simultaneous pericyte and endothelial targeting but also greater toxicity (hypertension, hand-foot syndrome, thyroid dysfunction). Cabozantinib's dual VEGFR2 and MET inhibition is particularly effective in renal cell carcinoma and hepatocellular carcinoma, where MET and AXL contribute to VEGF inhibitor resistance.

Resistance Mechanisms and Vessel Normalisation

Primary and acquired resistance to anti-VEGF therapy arise through upregulation of compensatory angiogenic pathways: fibroblast growth factor (FGF2) secreted by tumour-associated fibroblasts, placental growth factor (PlGF) signalling through VEGFR1, angiopoietin-2 (ANG2) promoting vessel remodelling, and PDGF-driven pericyte recruitment that stabilises vessels independent of VEGFA signalling. Sunitinib resistance is frequently mediated by pericyte coverage of tumour vessels, which renders them less VEGF-dependent and more structurally stable despite VEGFR TKI treatment.

A counterintuitive consequence of anti-VEGF therapy is tumour vessel normalisation: low-dose bevacizumab transiently reduces vessel density, diameter, and permeability, improving blood flow and drug delivery to previously poorly perfused tumour regions. This normalisation window — characterised by improved pericyte coverage, reduced branching, and more uniform perfusion — provides a rationale for combining anti-VEGF agents with chemotherapy or immunotherapy. Bevacizumab improves intratumoral immune cell access by reducing vascular barriers, providing mechanistic synergy with PD-1 checkpoint inhibitors (atezolizumab+bevacizumab is approved in hepatocellular carcinoma, IMbrave150 trial).

Key Takeaways

• ·Tumour hypoxia stabilises HIF-1α by inhibiting PHD enzyme activity, blocking VHL-mediated ubiquitination — driving 50-fold VEGFA transcriptional induction. Oncogenic RAS, PI3K/AKT/mTOR pathway activation, and STAT3 also drive VEGFA expression in normoxic cancer cells.
• ·The VEGFA→VEGFR2 signalling cascade activates PI3K/AKT/mTOR (endothelial survival), PLCγ/PKC (proliferation), and SRC-mediated VE-cadherin phosphorylation (vascular permeability) — the molecular drivers of tumour neovascularisation.
• ·Bevacizumab was the first anti-angiogenic approved in oncology (metastatic colorectal cancer, 2004); it is now approved across six cancer types in combination with chemotherapy or targeted agents.
• ·Resistance to VEGF pathway inhibitors is driven by FGF2, PlGF, and ANG2 upregulation as alternative pro-angiogenic factors — motivating multi-target approaches such as lenvatinib (VEGFR+FGFR+RET) and cabozantinib (VEGFR2+MET).
• ·Vessel normalisation under anti-VEGF therapy transiently improves tumour perfusion and immune cell infiltration, providing mechanistic rationale for anti-VEGF + immunotherapy combinations approved in hepatocellular carcinoma (atezolizumab+bevacizumab, IMbrave150).